Extended Data Table 2 PD-L1 expression status by SP263 and 22C3 CPS score in all patients

From: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial

  1. PD-L1, programmed death ligand 1; vCPS, visualized combined positive score; CPS, combined positive score.
Back to article page